Takaya Inagaki

Dr. Takaya Inagaki

Kindai University
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TITakaya Inagaki
Takaya Inagaki
Hiroshi DoiHiroshi Doi
Hiroshi Doi
NINaoko Ishida
Naoko Ishida
ARAritoshi Ri
Aritoshi Ri
STSaori Tatsuno
Saori Tatsuno
YNYasumasa Nishimura
Yasumasa Nishimura
Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage lung cancer. The purpose of this study was to investigate the optimal dose distribution and prognostic factors for local control (LC) after SBRT for lung cancer. A total of 104 lung tumors from 100 patients who underwent SBRT using various treatment regimens were analyzed. Dose distributions were corrected to the biologically effective dose (BED). Clinical and dosimetric factors were tested for association with LC after SBRT. The median follow-up time was 23.8 months (range, 3.4–109.8 months) after SBRT. The 1- and 3-year LC rates were 95.7% and 87.7%, respectively. In univariate and multivariate analyses, pathologically confirmed squamous cell carcinoma (SQ), T2 tumor stage, and a Dmax < 125 Gy (BED10) were associated with worse LC. The LC rate was significantly lower in SQ than in non-SQ among tumors that received a Dmax < 125 Gy (BED10) (p = 0.016). However, there were no significant differences in LC rate between SQ and non-SQ among tumors receiving a Dmax ≥ 125 Gy (BED10) (p = 0.198). To conclude, SQ, T2 stage, and a Dmax < 125 Gy (BED10) were associated with poorer LC. LC may be improved by a higher Dmax of the planning target volume.

7 December 2022 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
TITakaya Inagaki
Takaya Inagaki
Hiroshi DoiHiroshi Doi
Hiroshi Doi
MIMasahiro Inada
Masahiro Inada
NINaoko Ishida
Naoko Ishida
ARAritoshi Ri
Aritoshi Ri
YNYasumasa Nishimura
Yasumasa Nishimura

19 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
TITakaya Inagaki
Takaya Inagaki
TITakaya Inagaki
Takaya Inagaki
RSRyuki Shimono
Ryuki Shimono
AAAzusa Awaya
Azusa Awaya
TSTetsuo Sonomura
Tetsuo Sonomura
A 60-year-old woman presented with abnormal genital bleeding. Colposcopy and cystoscopy revealed black pigmented lesions in the vulva, vaginal vestibule, vaginal fornix, external urethral orifice, and urethral mucosa. The patient was diagnosed with vaginal malignant melanoma and urethral invasion. Because the melanoma was confined to the vagina and urethra, high-dose-rate brachytherapy using Ir-192 was selected. Vaginal lesions were irradiated using a vaginal applicator and the urethral lesions were irradiated by inserting a flexible catheter into the urethral catheter. The total radiation dose was 48 Gy in eight fractions. Pembrolizumab was started one month after radiotherapy. All black pigmented lesions disappeared within six months after brachytherapy. There was no sign of recurrence at 15 months after treatment. Adverse events included Grade 2 perivaginal inflammation at 6 weeks after treatment and Grade 3 vaginal stenosis at 15 months after treatment. The combination of intracavitary irradiation using a vaginal applicator and transurethral irradiation using a flexible catheter within a urethral catheter enabled delivery of an adequate tumor dose.

19 July 2026 in JMIR Preprints
Verified
Preprint
Open access
SMShota Miyoshi
Shota Miyoshi
NINobuki Imano
Nobuki Imano
TSTetsuo Saito
Tetsuo Saito
HOHiroki Ochi
Hiroki Ochi
TKTerufumi Kawamoto
Terufumi Kawamoto
YMYuji Murakami
Yuji Murakami
BACKGROUND Bleeding is a common complication of advanced gastrointestinal malignancies. Although radiotherapy is an effective hemostatic treatment, dose-fractionation remains unclear. Single-fraction 8 Gy radiotherapy has been demonstrated in palliative irradiation for conditions such as bone and liver metastases; however, its effectiveness in hemostatic radiotherapy remains uncertain. OBJECTIVE This study aims to prospectively evaluate the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. METHODS This is a prospective, multicenter, single-arm, open-label phase II trial evaluating single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. A total of 47 patients will be enrolled from 12 institutions in Japan. The primary endpoint is the hemostasis rate at 4 weeks after radiotherapy in the intention-to-treat population. Secondary endpoints include hemostasis rates at other time points, changes in hemoglobin levels, transfusion requirements, incidence of rebleeding, rebleeding-free interval, salvage treatment use, overall survival, antiemetic use, patient-reported toxicity, and health-related quality of life. RESULTS The study protocol was approved by the Hiroshima University Hospital Institutional Review Board in October 2025, and patient enrollment began in the same month. Recruitment is ongoing. CONCLUSIONS The STABLE study will provide prospective evidence regarding the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. The findings may help increase access to a less burdensome hemostatic approach for patients with bleeding gastrointestinal malignancies. CLINICALTRIAL This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; UMIN000059269).

31 December 2024 in Brachytherapy
Verified
Journal Article
Closed access
TITakaya Inagaki
Takaya Inagaki
YNYasutaka Noda
Yasutaka Noda
YIYuya Iwahashi
Yuya Iwahashi
TNTakahiro Naka
Takahiro Naka
MKMaria Kojima
Maria Kojima
TSTetsuo Sonomura
Tetsuo Sonomura